96 related articles for article (PubMed ID: 20609387)
1. In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction.
Amet N; Gacad M; Petrosyan A; Pao A; Jordan SC; Toyoda M
Transpl Immunol; 2010 Aug; 23(4):170-3. PubMed ID: 20609387
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction.
Sharma KG; Radha R; Pao A; Amet N; Baden L; Jordan SC; Toyoda M
Transpl Immunol; 2010 Jul; 23(3):117-20. PubMed ID: 20450974
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory effects of combination of pooled human gammaglobulin and rapamycin on cell proliferation and apoptosis in the mixed lymphocyte reaction.
Toyoda M; Petrosyan A; Pao A; Jordan SC
Transplantation; 2004 Oct; 78(8):1134-8. PubMed ID: 15502709
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
[TBL] [Abstract][Full Text] [Related]
5. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation.
MacMillan HF; Lee T; Issekutz AC
Clin Immunol; 2009 Aug; 132(2):222-33. PubMed ID: 19447680
[TBL] [Abstract][Full Text] [Related]
7. Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells.
Issekutz AC; Rowter D; Miescher S; Käsermann F
Clin Immunol; 2015 Oct; 160(2):123-32. PubMed ID: 25982320
[TBL] [Abstract][Full Text] [Related]
8. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors.
Tha-In T; Metselaar HJ; Tilanus HW; Boor PP; Mancham S; Kuipers EJ; de Man RA; Kwekkeboom J
Transplantation; 2006 Jun; 81(12):1725-34. PubMed ID: 16794540
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages.
Andersson J; Skansén-Saphir U; Sparrelid E; Andersson U
Clin Exp Immunol; 1996 May; 104 Suppl 1():10-20. PubMed ID: 8625537
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin.
Zhuang Q; Mazer B
J Allergy Clin Immunol; 2001 Aug; 108(2):229-34. PubMed ID: 11496239
[TBL] [Abstract][Full Text] [Related]
11. Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.
Matz M; Lehnert M; Lorkowski C; Fabritius K; Unterwalder N; Doueiri S; Weber UA; Mashreghi MF; Neumayer HH; Budde K
Transpl Int; 2012 Oct; 25(10):1106-16. PubMed ID: 22816666
[TBL] [Abstract][Full Text] [Related]
12. Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens.
Millán O; Jiménez O; Fortuna V; Barceló JJ; Brunet M
Int J Immunopathol Pharmacol; 2006; 19(2):317-30. PubMed ID: 16831299
[TBL] [Abstract][Full Text] [Related]
13. Differential modulation of cord blood and peripheral blood monocytes by intravenous immunoglobulin.
Gille C; Dreschers S; Spring B; Tárnok A; Bocsi J; Poets CF; Orlikowsky TW
Cytometry B Clin Cytom; 2012 Jan; 82(1):26-34. PubMed ID: 21812105
[TBL] [Abstract][Full Text] [Related]
14. Combined standard and novel immunosuppressive substances affect B-lymphocyte function.
Matz M; Lehnert M; Lorkowski C; Fabritius K; Weber UA; Mashreghi MF; Neumayer HH; Budde K
Int Immunopharmacol; 2013 Apr; 15(4):718-25. PubMed ID: 23499640
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway.
Prasad NK; Papoff G; Zeuner A; Bonnin E; Kazatchkine MD; Ruberti G; Kaveri SV
J Immunol; 1998 Oct; 161(7):3781-90. PubMed ID: 9759905
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies.
Bayry J; Fournier EM; Maddur MS; Vani J; Wootla B; Sibéril S; Dimitrov JD; Lacroix-Desmazes S; Berdah M; Crabol Y; Oksenhendler E; Lévy Y; Mouthon L; Sautès-Fridman C; Hermine O; Kaveri SV
J Autoimmun; 2011 Feb; 36(1):9-15. PubMed ID: 20970960
[TBL] [Abstract][Full Text] [Related]
17. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
Keller K; Daniel C; Schöcklmann H; Endlich KH; Kerjaschki D; Johnson RJ; Hugo C
Nephrol Dial Transplant; 2006 Oct; 21(10):2724-35. PubMed ID: 16861242
[TBL] [Abstract][Full Text] [Related]
18. Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression.
Ferri N; Granata A; Pirola C; Torti F; Pfister PJ; Dorent R; Corsini A
Mol Pharmacol; 2008 Jul; 74(1):144-53. PubMed ID: 18413661
[TBL] [Abstract][Full Text] [Related]
19. CD40-activated B cells from patients with systemic lupus erythematosus can be modulated by therapeutic immunoglobulins in vitro.
Néron S; Boire G; Dussault N; Racine C; de Brum-Fernandes AJ; Côté S; Jacques A
Arch Immunol Ther Exp (Warsz); 2009; 57(6):447-58. PubMed ID: 19866343
[TBL] [Abstract][Full Text] [Related]
20. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
